Retatrutide
Reviews
Description
Retatrutide is an investigational synthetic peptide developed as a multi-receptor agonist targeting metabolic pathways involved in glucose regulation, appetite control, and energy balance. It is designed to activate three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Retatrutide is currently being studied in clinical trials for its potential role in metabolic and weight-related conditions.
In clinical research, retatrutide has been investigated for its potential role in:
Supporting weight reduction in individuals with obesity or overweight
Improving glycemic control in type 2 diabetes
Modulating appetite and satiety signaling
Enhancing energy expenditure
Influencing lipid metabolism and cardiometabolic risk markers
It is believed to work by simultaneously targeting GLP-1, GIP, and glucagon pathways, which may contribute to reduced caloric intake, improved insulin sensitivity, and increased metabolic activity. Early-phase and mid-phase clinical trials have shown promising results in weight reduction and metabolic improvements; however, retatrutide remains investigational and is not yet approved for general medical use. Larger and longer-term studies are ongoing to further evaluate its safety, efficacy, and long-term outcomes.
For research purposes only.
Disclaimer
For Research Purposes only.
Used Solely for in vitro experiments and cannot be:
- Used in clinical trials involving humans.
- Administered to humans as part of an experiment or investigation.
- Supplied to another party for human investigational use.
Storage Conditions: Store at 2-8 °C; reconstituted material refrigerated and used within 6 weeks.